STOCK TITAN
  1. Home
  2. News
  3. VXRT

Vaxart Inc - VXRT STOCK NEWS

Welcome to our dedicated news page for Vaxart (Ticker: VXRT), a resource for investors and traders seeking the latest updates and insights on Vaxart.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vaxart's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vaxart's position in the market.

News
Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Vaxart announces positive topline results for its oral pill vaccine candidate in reducing norovirus infection, gastroenteritis, and viral shedding. The company establishes proof of concept for its vaccine platform in two human challenge studies. Vaxart also provides updates on its norovirus and COVID-19 vaccine programs. Financial results show a net loss of $17.4 million for Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.48%
Tags
earnings
-
News
Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers
Rhea-AI Summary
Vaxart, Inc. has dosed the first subject in its Phase 1 clinical trial for its oral pill bivalent norovirus vaccine candidate. The trial aims to evaluate the ability of the vaccine to induce breast milk antibodies and transfer them to young infants. Norovirus affects around 21 million people in the US annually, with 15% of children under 5 contracting the virus each year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.08%
Tags
clinical trial
-
News
Vaxart to Host Third Quarter 2023 Business Update and Financial Results Conference Call on November 2
Rhea-AI Summary
Vaxart, Inc. will provide a business update and report financial results for Q3 2023 on November 2, 2023. Conference call to be held at 4:30 p.m. ET. Investors can submit written questions in advance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
conferences earnings
News
Vaxart to Present at World Vaccine Congress Europe 2023 on October 18-19
Rhea-AI Summary
Vaxart to present at World Vaccine Congress Europe 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
conferences
-
News
Vaxart to Participate in Fireside Chat at 2023 Cantor Global Healthcare Conference
Rhea-AI Summary
Vaxart to participate in fireside chat at Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.05%
Tags
conferences
-
News
Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate
Rhea-AI Summary
Vaxart announces positive Phase 2 data for norovirus vaccine candidate, showing 29% reduction in infection rate and 85% decrease in viral shedding. No vaccine-related serious adverse events reported. Potential public health benefits and further analysis underway for larger Phase 2b study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.5%
Tags
clinical trial
News
Vaxart Provides Business Update and Reports Second Quarter 2023 Financial Results
Rhea-AI Summary
Vaxart, Inc. announces business update and financial results for Q2 2023. Preliminary data from Phase 2 norovirus vaccine trial shows positive results. Cash runway extended into Q3 2024. Conference call scheduled for 4:30 p.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.67%
Tags
earnings
-
News
Vaxart to Host Second Quarter 2023 Business Update and Financial Results Conference Call on August 3
Rhea-AI Summary
Vaxart, Inc. (NASDAQ: VXRT) will provide a business update and report financial results for Q2 2023 on August 3, 2023. The conference call hosted by the senior management team will begin at 4:30 p.m. ET. Investors can access the webcast and submit written questions in advance. A replay of the webcast will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.6%
Tags
conferences earnings
-
News
Vaxart Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate
Rhea-AI Summary
Vaxart, Inc. announced positive topline data from the Phase 2 clinical trial of its oral pill bivalent norovirus vaccine candidate. Both doses showed robust serum immune responses with no statistical difference. The vaccine was well tolerated with no serious adverse events. Mucosal and cell-based assay data will be available later.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
clinical trial
News
Vaxart Stockholders Approve All Four Proposals in the 2023 Proxy Statement
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
none
Stock VXRT logo
Vaxart Inc

Nasdaq:VXRT

VXRT Rankings

#4047 Ranked by Market Cap
#4907 Ranked by Stock Gains
N/A Ranked by Dividends

VXRT Stock Data

158.23M
156.96M
0.97%
18.13%
9.89%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
South San Francisco

About VXRT

since its founding in 2004, vaxart has pursued a vision of advancing vaccines—to make them as tablets rather than injections. the company’s proprietary oral vaccine delivery platform is suitable to deliver any recombinant vaccine, positioning vaxart to introduce oral forms of multiple vaccines in the rapidly growing global vaccines market.